- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04731844
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Peter Van Veldhuizen
- Phone Number: (585) 275-3746
- Email: Peter_Vanveldhuizen@URMC.Rochester.edu
Study Locations
-
-
New York
-
Rochester, New York, United States, 14623
- Recruiting
- University of Rochester
-
Principal Investigator:
- Peter Van Veldhuizen, MD
-
Contact:
- Peter Van Veldhuizen
- Phone Number: 585-275-3746
- Email: Peter_Vanveldhuizen@URMC.Rochester.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.
- Age ≥ 18 years of age.
- Karnofsky performance status (KPS) of ≥ 70%.
- Subjects with either 1) non-metastatic biopsy proven adenocarcinoma of the prostate who have chosen AS the treatment option for their prostate cancer or 2) have the diagnosis of either MGUS or low-risk SMM and are currently on observation alone.
For patients with MGUS or low-risk SMM, diagnosis must be according to the definition of the International Myeloma Working Group (IMWG).
- MGUS: serum M-protein <3.0g/dL, <10% clonal plasma cells (PCs) in the bone marrow, and absence of end-organ damage (CRAB criteria) that can be attributed to the plasma cell disorder.
SMM: serum M-protein of ≥3.0g/dL or a proportion of clonal PCs in the BM of ≥10% but <60%, and no evidence of end organ damage as described below.
Absence of end organ damage is defined by absence of CRAB criteria:
- C: Absence of hypercalcemia, defined as calcium ≤11mg/dL.
- R: Absence of renal failure, defined as serum creatinine ≤2.0mg/dL.
- A: Absence of anemia, defined as hemoglobin ≥10g/dL.
- B: Absence of lytic bone lesions per IMWG recommendations: One of either PET-CT, low-dose whole-body CT, or whole- body MRI. Increased uptake on PET-CT alone is not adequate for the diagnosis of multiple myeloma; evidence of underlying osteolytic bone destruction is needed on the CT portion of the examination.
At least one of the risk factors below that portends for an increased risk of progression to MM:
- Abnormal serum free light chain ratio.
- M-spike ≥2.0g/dL.
- ≥ 20% bone marrow clonal plasma cells.
- Immunoparesis ≥20% reduction from institutional normal standard of uninvolved immunoglobulins.
Exclusion Criteria
- Currently taking supplements containing either curcumin or piperine.
- Plan to start any additional over the counter supplements prior to or during trial period.
- For prostate cancer patients must not be planning to undergoing primary curative therapy for their prostate cancer (radiation, surgery, brachytherapy).
- For MGUS/ SMM patients, must not have had evidence of disease progression which might require treatment during the one-year study period.
- Other: symptomatic plasma cell leukemia, amyloidosis, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein).
- Subject is pregnant or breast feeding, or planning to become pregnant during the treatment period.
- Evidence of any of the following conditions per subject self-report or medical chart review: Major surgery or significant traumatic injury occurring within 4 weeks before enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prostate Cancer
Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
|
Curcumin with piperine is a well-tolerated over-the-counter supplement.
Other Names:
|
Experimental: Smoldering Multiple Myeloma (SMM)
Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
|
Curcumin with piperine is a well-tolerated over-the-counter supplement.
Other Names:
|
Experimental: Monoclonal Gammopathy of Unknown Significance (MGUS)
Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months
|
Curcumin with piperine is a well-tolerated over-the-counter supplement.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate of Curcumin & Piperine supplementation in patients on AS for either early stage prostate cancer or MGUS.
Time Frame: From date of enrollment until the date of first documented response assessed up to 12 months
|
Measure of time from study enrollment until response
|
From date of enrollment until the date of first documented response assessed up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Measure of time from study enrollment until progression.
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter Van Veldhuizen, University of Rochester Wilmot Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Urogenital Neoplasms
- Neoplasms by Site
- Hematologic Diseases
- Genital Neoplasms, Male
- Prostatic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Blood Protein Disorders
- Precancerous Conditions
- Hypergammaglobulinemia
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Smoldering Multiple Myeloma
- Paraproteinemias
- Monoclonal Gammopathy of Undetermined Significance
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Cytochrome P-450 Enzyme Inhibitors
- Curcumin
- Piperine
Other Study ID Numbers
- UMLT20123
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Curcumin plus Piperine
-
National Institute of CancerologíaSabinsa CorporationRecruiting
-
University of Southern CaliforniaNational Cancer Institute (NCI)Not yet recruitingPolycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myelodysplastic Syndrome | Clonal Cytopenia of Undetermined SignificanceUnited States
-
Denise MafraCompleted
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingPain | Malignant Neoplasm | Urinary Urgency | Bladder SpasmUnited States
-
Saiful Anwar HospitalCompletedSystemic Lupus ErythematosusIndonesia
-
Hospital de MataróInstituto de Salud Carlos III; Consorci Sanitari del MaresmeRecruitingStroke | Oropharyngeal Dysphagia | Stroke, Acute | Swallowing DisorderSpain
-
Rehab WeridaCompleted
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedFocus of the Study: Normal VolunteersUnited States
-
Hospital de MataróCompletedDeglutition DisordersSpain
-
H.K.E.S's S.Nijalingappa Institute of Dental Science...Unknown